Loading clinical trials...
Loading clinical trials...
A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy
Conditions
Interventions
XEN496
Placebo
Locations
20
United States
Children's Hospital of Orange County
Orange, California, United States
UCSF Medical Center
San Francisco, California, United States
Children's Hospital of Colorado
Aurora, Colorado, United States
Children's National Health System
Washington D.C., District of Columbia, United States
Northwest Florida Clinical Research Group
Gulf Breeze, Florida, United States
Anne & Robert H. Lurie Children's Hospital
Chicago, Illinois, United States
Start Date
March 29, 2021
Primary Completion Date
May 16, 2023
Completion Date
May 16, 2023
Last Updated
August 23, 2024
NCT06315322
NCT06700356
NCT02531880
NCT05289934
NCT05871372
NCT07445074
Lead Sponsor
Xenon Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions